The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | EMERALD-3: tremelimumab + durvalumab with or without lenvatinib combined with TACE in HCC
Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, provides an overview of the rationale and study design of the EMERALD-3 trial (NCT05301842), a randomised Phase III study of tremelimumab plus durvalumab with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients with locoregional hepatocellular carcinoma (HCC). Dr Abou-Alfa also discusses the limitations of sorafenib and emphasises the importance of ensuring widespread access to new effective therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
